Disease & disorder
bladder adenocarcinoma
MONDO:0002751
A carcinoma that arises from glandular epithelial cells of the urinary bladder
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
Loading mapped interventions…
MONDO disease family
Loading verified ontology relationships…
Recruiting studies by city
Loading research-site locations…
Trial status
Loading…
Trial phase
Loading…
Study start year
Loading…
Investigated drug interventions
Loading…
Background context
bladder adenocarcinoma
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
2 shownTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13
RECRUITINGNivolumab and Ipilimumab in Treating Patients With Rare TumorsNCT02834013 · 2017-01-30
ACTIVE_NOT_RECRUITINGDrugs being studied
Research locations
AllentownPennsylvania, United States2Ann ArborMichigan, United States2AtlantaGeorgia, United States2AventuraFlorida, United States2BaltimoreMaryland, United States2Baton RougeLouisiana, United States2BellevueWashington, United States2BethesdaMaryland, United States2BillingsMontana, United States2BirminghamAlabama, United States2BoiseIdaho, United States2BuffaloNew York, United States2
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.